Aduro Biotech, Inc.

Brief Description

Aduro is a clinical-stage cancer immunotherapy company with multiple therapeutic approaches in development that have the potential to yield powerful immunotherapy combinations. The company’s lead technology platforms are based on LADD (live, attenuated, double-deleted Listeria mononcytogenes) and CDNs (cyclic dinucleotides). Both are proprietary platforms. LADD strains have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. 

Aduro Biotech merged with Chinook Therapeutics in 2020. The combined company operates as Chinook Therapeutics.


Tech Category

  • Medical Therapeutics

In the News

Join the IPIRA Mailing List




Accessibility | Nondiscrimination | Privacy